

## Lead optimization and candidate selection of PD-L1 small molecule inhibitor for non-clinical study

ILab



ONCOLOGY	Candidate
Product Type	Small molecules
Indication	As an alternative treatment for cancer patients who could potentially benefit using PD-1/PD-L1 antibody therapy, especially NSCLC and brain cancer patients.
Target	PD-L1 protein expressed on cell surface
MoA(Mechanism of Action)	Blocking PD-1/PD-L1 linkage by inducing PD-L1 homodimerization and internalization
Competitiveness	<ul style="list-style-type: none"> <li>• PD-L1 small molecule inhibitor has an advantage over antibody drug to handle immune related adverse event, especially in NSCLC patients where the incidence is high (7%) and can be fatal.</li> <li>• Oral administration avoid invasive administration and hospitalization.</li> <li>• At least two leads compound showed potent in vivo mouse efficacy using MC38 colon cancer model when administrated P.O.</li> <li>• In preliminary study, the leads do not show neurotoxicity which could be a hurdle in clinical application.</li> </ul>
Development Stage	Candidate
Route of Administration	Oral